Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
2004 · JNCI Journal of the National Cancer Institute · 271 citations
https://doi.org/10.1093/jnci/djh133
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
5
Papers
322
Citations
3
h-index
3
i10-index
W. Eiermann is an academic researcher from Rotkreuzklinikum München. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Cancer Treatment and Pharmacology & Breast Cancer Treatment Studies. The author has an h-index of 3, co-authored 5 publications.
Click to start Chat